INT209345

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.83
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (AGTR2) signal transducer activity (AGTR2)
AGTR2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Calcium channel 5 99.30 Very High Very High Very High
Pain 1 83.12 Quite High
abdominal pain 11 70.92 Quite High
Inflammatory marker 1 50.00 Quite Low
Inflammation 4 41.12 Quite Low
Antihistamine 12 5.00 Very Low Very Low Very Low
antagonist 8 5.00 Very Low Very Low Very Low
corticosteroid 6 5.00 Very Low Very Low Very Low
bradykinin 4 5.00 Very Low Very Low Very Low
beta blocker 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Weight Loss 1 100.00 Very High Very High Very High
Pressure And Volume Under Development 166 98.94 Very High Very High Very High
Proteinuria 9 98.68 Very High Very High Very High
Membranous Glomerulonephritis 17 98.00 Very High Very High Very High
Disease 31 97.44 Very High Very High Very High
Renal Disease 11 96.92 Very High Very High Very High
Hereditary Angioedema 142 95.20 Very High Very High Very High
Heart Rate Under Development 3 94.96 High High
Intestinal Obstruction 1 88.40 High High
Diarrhoea 3 84.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This article discusses the place of combination therapy in arterial hypertension (HTN) and concentrates on the potential advantage of Exforge® (Novartis), the first commercially available combination of a dihydropyridine calcium channel blocker (CCB) (amlodipine) and an angiotensin II receptor blocker (ARB) (valsartan).
Negative_regulation (blocker) of angiotensin II receptor associated with pressure and volume under development and calcium channel
1) Confidence 0.17 Published 2010 Journal Core evidence Section Body Doc Link PMC2899780 Disease Relevance 0.27 Pain Relevance 0.05
The management of membranous glomerulonephritis in a patient with HAE would be challenging as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin 2 receptor blockers (ARBs) which effectively reduce proteinuria and slow the progression of the renal disease [2] cause angioedema which precludes their use in patients with HAE [3].
Negative_regulation (blockers) of angiotensin 2 receptor associated with pressure and volume under development, membranous glomerulonephritis, renal disease and proteinuria
2) Confidence 0.12 Published 2008 Journal J Med Case Reports Section Body Doc Link PMC2577685 Disease Relevance 1.09 Pain Relevance 0
(b) angioedema due to angiotensin converting enzyme inhibitors and angiotensin-II receptor blockers
Negative_regulation (blockers) of angiotensin-II receptor associated with pressure and volume under development
3) Confidence 0.08 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 2.90 Pain Relevance 0.15
It has been suggested that angiotensin II receptor inhibitors will not be included, though it remains unclear whether this can be interpreted as ad hoc policy at the behest of industry lobbying.
Negative_regulation (inhibitors) of angiotensin II receptor
4) Confidence 0.06 Published 2007 Journal Aust New Zealand Health Policy Section Body Doc Link PMC1894805 Disease Relevance 0 Pain Relevance 0
Therapeutic interventions with medications like statins, angiotensin II receptor blocking agents as well as weight loss, have also shown improvement in LAEI and SAEI which may suggest lowering of cardiovascular risk.
Negative_regulation (loss) of angiotensin II receptor associated with weight loss
5) Confidence 0.03 Published 2010 Journal Nutr Metab (Lond) Section Body Doc Link PMC2911454 Disease Relevance 0.56 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox